Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5423 · 7 trials · 5 indications
LAR was assessed on Day 6 as minimum percentage of FEV1 over 3 to 7 hours based on the analysis of the minimum percentage of FEV1 remaining over 3 to 7 hours post allergen challenge (post AC) compared to pre allergen challenge (pre AC) FEV1
| Arm | Type | Description |
|---|---|---|
| AZD5423 | EXPERIMENTAL | New study drug |
| Budesonide | ACTIVE_COMPARATOR | Comparator to which the new study drug will be compared |
| Placebo | PLACEBO_COMPARATOR | No drug to which both other arms will be compared |
| 1 | EXPERIMENTAL | AZD5423 75ug |
| 2 | EXPERIMENTAL | AZD5423 300ug |
| 3 | ACTIVE_COMPARATOR | Budesonide 200 microgram |
| 4 | PLACEBO_COMPARATOR | Placebo |
| 5 | EXPERIMENTAL | AZD5423 inhalation Turbuhaler |
| 6 | EXPERIMENTAL | AZD5423, New Dry Powder Inhaler |
| A | EXPERIMENTAL | Drug: AZD5423 |
| B | PLACEBO_COMPARATOR | Drug: Placebo |
| Name | Type | Description |
|---|---|---|
| AZD5423 | DRUG | oral inhaled |
| Budesonide | DRUG | oral inhaled |
| Placebo | DRUG | oral inhaled |
| Budesonide 200 microgram | DRUG | Dry powder for inhalation twice daily 7 days |
Inclusion Criteria: * Provision of signed and dated informed consent prior to conducting any study specific procedures * Men or women aged ≥ 40 years * Men or post-menopausal or surgically sterile women. Women will be considered post-menopausal if they have been amenorrheic for at least 12 months, ...
AZD5423 is an investigational small molecule being developed for respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). It has been studied in healthy volunteers and patients with mild asthma or COPD. The drug is administered via inhalation and is currently in clinical development, with no approved indications.
AZD5423 is a small molecule developed by AstraZeneca for respiratory diseases. While its specific molecular target is not disclosed in available clinical trial information, it is being evaluated for its efficacy in asthma and COPD. The drug is administered via inhalation and has completed Phase 1 and Phase 2 trials.
AZD5423 is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca has sponsored clinical trials of AZD5423 in asthma, COPD, and healthy volunteer studies across multiple countries.
AZD5423 is in Phase 2 clinical development for asthma and COPD, with Phase 1 studies also completed. All three clinical trials of AZD5423 have been completed, and the drug is not yet approved by regulatory authorities. It remains an investigational agent under evaluation.
AZD5423 has been studied in three completed clinical trials: NCT01225549 (Phase 2, mild asthma allergen challenge), NCT01310322 (Phase 1, healthy subjects and mild asthmatics), and NCT01555099 (Phase 2, COPD with formoterol background therapy). A fourth trial, NCT01635985, investigated pharmacokinetics in healthy subjects.
AZD5423 is a distinct investigational compound developed by AstraZeneca, not a marketed asthma medication. It is being studied for asthma and COPD, but it is not yet approved. No alternative names for AZD5423 have been disclosed in clinical trial records.